2 years ago

Enterprise Therapeutics Secures £26M Series B Follow-on to Advance Respiratory Therapies

  • Enterprise Therapeutics, a Brighton, UK-based biopharmaceutical company dedicated to the discovery and development of novel therapies for respiratory disease, raised £26M in Series B follow-on funding

  • The round was led by Panakes Partners with participation from existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group

  • The company plans to use the funds to accelerate the Phase 2a clinical trial of its lead program, ETD001, to deliver clinical proof of concept to treat cystic fibrosis and expand clinical activities into Italy via addition of clinical investigator sites and progression of its other preclinical programs targeting mucus congestion.

      • ProblemHealthcare

      "to deliver clinical proof of concept to treat cystic fibrosis and expand clinical activities into Italy via addition of clinical investigator sites and progression of its other preclinical programs targeting mucus congestion"

      Solution

      "a novel low molecular weight compound that targets the ENaC ion channel in the airway epithelium, increasing the hydration and clearance of mucus"

      Covered on